Table 2 Details of treatments received (N = 68)
Endometrium N = 61 | Cervix N = 7 | |
|---|---|---|
Surgery | ||
Frontline | 56 (92%) | 5 (71%) |
Free margins | 50 (89%) | 3 (60%) |
Pelvic LND | 49 (88%) | 4 (80%) |
Para-aortic LND | 40 (71%) | 5 (100%) |
Radiotherapy | ||
Radiotherapy alone | 26 (43%) | 1 (14%) |
Radio-chemotherapy (concomitant or sequential) | 18 (30%) | 3 (43%) |
Brachytherapy | 35 (57%) | 4 (57%) |
Chemotherapy | ||
Carboplatin-paclitaxel | 28 (46%) | 3 (43%) |
Carboplatin-paclitaxel-bevacizumab | 21 (75%) | 2 (29%) |
CAP | 1 (4%) | 1 (14%) |
Carboplatin monotherapy | 2 (7%) | 0 |
Carboplatin-adriamycin | 2 (7%) | 0 |
Cisplatin monotherapy | 1 (4%) | 0 |